Age‐related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs
Authors:
- Morey A. BlinderMBMorey A. Blinder
- Francis VekemanFVFrancis Vekeman
- Medha SasaneMSMedha Sasane
- Alex TraheyATAlex Trahey
- Mei Sheng DuhMDMei Sheng Duh
- 17 January 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (5) , 828-835
Abstract
Background: This study explored the blood transfusion patterns, SCD complications, utilization of iron chelation therapies (ICT), healthcare resource use, and costs in pediatric, transitioning (18 years old) and adult patients with SCD.Procedure: Data from Florida (1998–2009), New Jersey (1996–2009), Missouri (1997–2010), Kansas (2001–2009), and Iowa (1998–2010) state Medicaid were used. Patients with ≥2 SCD diagnoses and ≥1 transfusion event were included. Rates of transfusion events, SCD complications, and proportion of eligible patients receiving ICT were calculated. ICT eligibility was defined as receiving ≥10 transfusions over lifetime. SCD complications included pain, pulmonary event, infection event, renal, cardiovascular, stroke, leg ulcers, and avascular necrosis. Regressions were used to assess risk factors for transfusion and identify the main drivers of costs.Results: The sample included 3,208 patients. The transfusion rate increased from 1‐year‐old to a peak at 16 years old, then dropped until age 26 and remained stable thereafter. In contrast the frequency of diagnoses for SCD complications increased markedly after age 16. Post‐transition patients (≥18 years old) were significantly associated with fewer transfusions (odds ratio: 0.80, P = 0.002). Among eligible patients for ICT, there was no statistically significant difference in total cost between the ICT and no ICT groups (adjusted cost difference, $136, P = 0.114).Conclusions: Patients transitioning to adult care received less transfusions and hydroxyurea, less ICT when eligible for chelation therapy, had higher healthcare costs and suffered from more frequent SCD related complications than pediatric patients. These findings highlight the changes in treatment patterns corresponding to transition to adult care. Pediatr Blood Cancer 2013; 60: 828–835.Keywords
This publication has 25 references indexed in Scilit:
- Transfusion and Chelation Practices in Sickle Cell Disease: A Regional PerspectivePediatric Hematology and Oncology, 2010
- Iron Metabolism and Iron Chelation in Sickle Cell DiseaseActa Haematologica, 2009
- Hepatic Iron Overload in Children With Sickle Cell Anemia on Chronic Transfusion TherapyJournal of Pediatric Hematology/Oncology, 2009
- Transfusion in the Patient With Sickle Cell Disease: A Critical Review of the Literature and Transfusion GuidelinesTransfusion Medicine Reviews, 2007
- Circumstances of death in adult sickle cell disease patientsAmerican Journal of Hematology, 2006
- A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.Blood, 2004
- Practical management of iron overloadBritish Journal of Haematology, 2001
- Progression of iron overload in sickle cell diseaseSeminars in Hematology, 2001
- Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell diseaseSeminars in Hematology, 2001
- Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapyBlood, 2000